NASDAQ: APVO
Aptevo Therapeutics Inc Stock Ownership - Who owns Aptevo Therapeutics?

Insider buying vs selling

Have Aptevo Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Grady Grant IiiDirector2025-11-1013,513$1.49
$20.13kBuy

1 of 1

APVO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when APVO insiders and whales buy or sell their stock.

APVO Shareholders

What type of owners hold Aptevo Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fuad Elhibri242.51%3,021,899$14.11MInsider
Scott C. Stromatt17.35%216,183$1.01MInsider
Jane A. Gross8.79%109,583$511.75kInsider
Shawnte Mitchell6.46%80,527$376.06kInsider
Randy Joe Maddux6.02%75,000$350.25kInsider
Michael Adelman5.65%70,426$328.89kInsider
Gsa Capital Partners LLP1.58%19,638$91.71kInstitution
Grady Grant Iii1.08%13,514$63.11kInsider
Geode Capital Management LLC1.07%13,337$62.28kInstitution
Vanguard Capital Management LLC1.02%12,713$59.37kInstitution

1 of 3

APVO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
APVO1.48%98.52%Net Buying
PCSA4.98%95.02%Net BuyingNet Buying
CDIO3.51%96.49%
SNGX0.25%99.75%Net Buying
MLEC0.48%99.52%

Aptevo Therapeutics Stock Ownership FAQ

Who owns Aptevo Therapeutics?

Aptevo Therapeutics (NASDAQ: APVO) is owned by 4.31% institutional shareholders, 287.87% Aptevo Therapeutics insiders, and 0.00% retail investors. Fuad Elhibri is the largest individual Aptevo Therapeutics shareholder, owning 3.02M shares representing 242.51% of the company. Fuad Elhibri's Aptevo Therapeutics shares are currently valued at $14.11M.

If you're new to stock investing, here's how to buy Aptevo Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.